---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件（20121822051534.pdf）的“原文Priscribing Information”为准
---------------------------------------------------------------
部分中文比拉斯汀处方资料（仅供参考）

中文名称: 比拉斯汀

英文名称： Bilastine

英文名称: BENZENEACETIC ACID, 4-(2-(4-(1-(2-ETHOXYETHYL)-1H-BENZIMIDAZOL-2-YL)-1-PIPERIDINYL)ETHYL-ALPHA, ALPHA-DIMETHYL-

英文同义词: BENZENEACETIC ACID, 4-(2-(4-(1-(2-ETHOXYETHYL)-1H-BENZIMIDAZOL-2-YL)-1-PIPERIDINYL)ETHYL-ALPHA, ALPHA-DIMETHYL-;2-[4-[2-[4-[1-(2-ethoxyethyl)benzoimidazol-2-yl]-1-piperidyl]ethyl]phenyl]-2-methyl-propanoic acid;4-[2-[4-[1-(2-Ethoxyethyl)-1H-benzimidazol-2-yl]-1-piperidinyl]ethyl]-alpha,alpha-dimethylbenzeneacetic acid;Bilastine

比拉斯汀（bilastine）为西班牙FAES制药公司开发的第2代组胺H1受体拮抗剂，在欧洲其治疗变应性鼻炎及慢性特发性荨麻疹，在美国季节性变应性鼻一结膜炎的疗效。在健康受试者和鼻炎患者中进行的研究表明：本品安全性良好，无常用抗组胺药物存在的镇静作用及心脏毒性。

Faes Farma's Bilaxten (Bilastine) now marketed in Spain
Faes Farma has begun distribution of Bilaxten (Bilastine), a next-generation antihistamine of quick and prolonged activity with a high-safety profile, prescribed for allergic rhinoconjunctivitis and urticaria.

Bilaxten is available in pharmacies since April. The emergence of Bilastine is a worldwide novelty, given that, since 2003, there had been no significant advances in the treatment of allergies with antihistamines.

After technical approval in the registry, granted on 28 September 2010 for Europe, Faes Farma has obtained administrative approvals to market Bilastine in 19 countries. The next step was the pricing and reimbursement scheme approval for the product in each of the countries, an issue that has already been solved in Spain.

Bilastine will be internationally marketed through top-class partners. Meranini, leading the promotion throughout Europe, will work in co-marketing with GlaxoSmithKline in Spain and Poland and with Pierre Fabra in France and Belgium, while collaborating with Vianex, the local pharmaceutical leader in Greece.

Outside Europe, Pfizer will launch Bilastine in Mexico; Nycomed will market it in Brazil, Merck Serono in India, Hikma in MENA and Yuhan in South Korea.

Meanwhile, agreements with other great markets are being closed, including: Japan, China, Southeast Asia, Central and South America.

Name Arzneimittel: Bilaxten®, Tabletten

Name des Wirkstoffs / der Wirkstoffe: Bilastin

Dosisstärke und galenische Form: Tabletten zu 20 mg

Anwendungsgebiet / Indikation: Symptomatische Behandlung der saisonalen allergischen Rhino-Konjunktivitis und Urtikaria.

ATC Code: R06AX29

IT-Nummer / Bezeichnung: 07.13.1./ Antihistaminica

Zulassungsnummer/n: 61446

Zulassungsdatum: 31.10.2011

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件（20121822051534.pdf）的“原文Priscribing Information”为准
---------------------------------------------------------------